Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBIO iBio	$0.57 -2.3%	$0.77	$0.56 ▼ $6.89	$9.47M	0.6	1.40 million shs	226,046 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
PRFX PainReform	$1.35 -2.2%	$1.55	$1.25 ▼ $16.63	$2.71M	0.57	1.06 million shs	11,344 shs
SNSE Sensei Biotherapeutics	$7.60 +1.5%	$7.81	$5.00 ▼ $17.40	$9.58M	0.26	68,383 shs	11,240 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBIO iBio	-1.33%	-7.42%	-28.03%	-26.71%	-62.42%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PRFX PainReform	+3.76%	+2.22%	-0.72%	-28.13%	+7.98%
SNSE Sensei Biotherapeutics	+0.19%	-13.12%	-10.39%	+5.43%	-40.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IBIO iBio	1.1802 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.6
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	0.775 of 5 stars	0.0	2.0	0.0	0.0	2.6	1.7	0.6
SNSE Sensei Biotherapeutics	4.7256 of 5 stars	3.7	5.0	0.0	4.8	3.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBIO iBio	3.00	Buy	$5.00	772.45% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
PRFX PainReform	2.00	Hold	N/A	N/A
SNSE Sensei Biotherapeutics	3.33	Buy	$55.00	623.78% Upside

Current Analyst Ratings Breakdown

Latest PRFX, PHXM, IBIO, and SNSE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/2/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$100.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBIO iBio	$375K	25.25	N/A	N/A	$1.41 per share	0.41
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	$2.08 per share	N/A
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$30.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	-$14.59M	-$147.33	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)
SNSE Sensei Biotherapeutics	-$30.16M	-$21.31	N/A	N/A	N/A	N/A	-72.13%	-61.35%	N/A

Latest PRFX, PHXM, IBIO, and SNSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	SNSE Sensei Biotherapeutics	-$6.20	-$3.91	+$2.29	-$3.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBIO iBio	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBIO iBio	0.05	1.76	1.76
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
PRFX PainReform	N/A	1.81	1.81
SNSE Sensei Biotherapeutics	N/A	7.64	7.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBIO iBio	7.90%
PHXM PHAXIAM Therapeutics	0.40%
PRFX PainReform	37.28%
SNSE Sensei Biotherapeutics	10.50%

Insider Ownership

Company	Insider Ownership
IBIO iBio	0.58%
PHXM PHAXIAM Therapeutics	1.94%
PRFX PainReform	34.40%
SNSE Sensei Biotherapeutics	23.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
PRFX PainReform	4	2.01 million	1.32 million	Not Optionable
SNSE Sensei Biotherapeutics	40	1.26 million	968,000	Not Optionable

PRFX, PHXM, IBIO, and SNSE Headlines

Recent News About These Companies

Q3 EPS Estimate for Sensei Biotherapeutics Lifted by Analyst

August 8, 2025 | americanbankingnews.com

Sensei (SNSE) Q2 Loss Narrows 31%

August 6, 2025 | fool.com

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

These 3 health tech stocks spiked 37% in a day; Time to buy?

August 4, 2025 | finbold.comF

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

July 30, 2025 | globenewswire.com

Sensei Biotherapeutics to execute 1-for-20 reverse stock split

June 13, 2025 | kalkinemedia.comK

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

June 13, 2025 | globenewswire.com

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025 | globenewswire.com

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

April 2, 2025 | globenewswire.com

Sensei Biotherapeutics announces initial results from solnerstotug trial portion

March 29, 2025 | markets.businessinsider.com

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

March 28, 2025 | globenewswire.com

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

March 27, 2025 | globenewswire.com

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

February 6, 2025 | zacks.com

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | markets.businessinsider.com

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | globenewswire.com

Sensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden Strengths

January 18, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX, PHXM, IBIO, and SNSE Company Descriptions

iBio NYSE:IBIO

$0.57 -0.01 (-2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.01 (+1.03%)

As of 05:26 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/8/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

PainReform NASDAQ:PRFX

$1.35 -0.03 (-2.17%)

Closing price 03:49 PM Eastern

Extended Trading

$1.37 +0.02 (+1.48%)

As of 05:38 PM Eastern

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Sensei Biotherapeutics NASDAQ:SNSE

$7.60 +0.11 (+1.46%)

Closing price 03:58 PM Eastern

Extended Trading

$7.60 0.00 (0.00%)

As of 04:20 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time